Biogen Inc. (BIIB) Revenue by Segment
Biogen revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Biogen's largest product or service was Rare Disease Product Revenue, with $601.70 million or 22% of revenue, up 10.8% from a year earlier. Next: Revenues from anti-cd20 therapeutic programs (19%), TYSABRI product (16%) and Fumarate (11%).
The fastest-growing product or service from a year earlier was Rare Disease Product Revenue (+10.8%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2017.
Biogen Inc.
Revenue breakdown
Fiscal quarters, from company filings
Biogen revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Rare Disease Product Revenue | $601.7M | $557.2M | $533.3M | $543.0M | 22% |
| Revenues from anti-cd20 therapeutic programs | $513.5M | $419.1M | $493.9M | $467.3M | 19% |
| TYSABRI product | $450.8M | $441.5M | $431.8M | $454.6M | 16% |
| Fumarate | $287.4M | $288.5M | $382.8M | $405.9M | 11% |
| Contract manufacturing and other revenue | $232.4M | $237.2M | $141.5M | $225.0M | 8% |
| Interferon | $225.1M | $227.5M | $246.9M | $246.7M | 8% |
| Biosimilars | $152.8M | $182.2M | – | $181.7M | 6% |
| Syfovre | $97.4M | – | – | – | 4% |
| Other Products | $70.8M | $55.4M | $55.3M | – | 3% |
| Alzheimer's Collaboration | $63.7M | $59.5M | $42.7M | $54.9M | 2% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Biogen?
Rare Disease Product Revenue: $601.70 million, or 22% of revenue, in Q2 fiscal 2026.
What are Biogen's main products and services?
By revenue in Q2 fiscal 2026: Rare Disease Product Revenue (22%), Revenues from anti-cd20 therapeutic programs (19%), TYSABRI product (16%) and Fumarate (11%).
